The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure.
The generic, dapagliflozin, is indicated to improve glycemic control in adults with Type 2 diabetes and to reduce heart failure hospitalization risk in diabetic patients with established cardiovascular disease or multiple risk factors, according to an April 7 agency update.
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that works by reducing the reabsorption of glucose and sodium in the kidneys.
The FDA said the generics carry the same warnings and precautions as the brand product, including risks of ketoacidosis and volume depletion. Common side effects include genital infections, nasopharyngitis and urinary tract infections.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
